Shu Fu Pai® Protein Short Peptides Beverage for the treatment of hypoalbuminemia in liver cirrhosis

Gao Chen; Qian Li; Junli Chen; Fei Huang; Chunjun Qin; Xianya He

Shu Fu Pai^® Protein Short Peptides Beverage for the treatment of hypoalbuminemia in liver cirrhosis

Am J Transl Res. 2023 Sep 15;15(9):5723-5729. eCollection 2023.

Authors

Gao Chen¹, Qian Li¹, Junli Chen², Fei Huang¹, Chunjun Qin¹, Xianya He¹

Affiliations

¹ Department of Infection, Deyang People's Hospital Deyang 618000, Sichuan, China.
² Department of Medical Records, Zhongjiang County Second People's Hospital Deyang 618107, Sichuan, China.

PMID: 37854233
PMCID: PMC10579008

Abstract

Objective: To investigate the clinical efficacy of Shu Fu Pai^® Protein Short Peptides Beverage in the treatment of hypoalbuminemia in liver cirrhosis.

Methods: A retrospective analysis was conducted on 289 patients with liver cirrhosis and hypoalbuminemia who were admitted to Deyang People's Hospital between April 2021 and April 2023. Among them, 148 patients treated with Shu Fu Pai^® Protein Short Peptides Beverage were assigned as an observation group and 141 patients treated with intravenous human albumin were the control group. Liver function, coagulation function before and after treatment, and complications after treatment were compared between the two groups. The patients whose albumin levels did not increase after treatment were counted, and the influencing factors were analyzed using univariate and multivariate analyses.

Results: After treatment, there was a significant improvement in liver function, serum albumin level, Child-Pugh score, inflammatory markers, and coagulation function in both groups (all P=0.001). However, no significant difference was found in the peripheral blood indicators between the two groups (P>0.05). Also, there was no significant difference in complications between the two groups (P=0.194). Logistic regression analysis showed that age, pre-treatment serum albumin level, disease type, and abnormal liver function markers were independent factors affecting the treatment outcome of hypoalbuminemia, and treatment regimen was not an influencing factor.

Conclusion: Shu Fu Pai^® Protein Short Peptides Beverage for hypoalbuminemia in liver cirrhosis is not inferior to intravenous human albumin for improving liver function, inflammatory markers, and coagulation function. The therapeutic effect on hypoproteinemia is independent of type of treatment regimen, which suggests that Shu Fu Pai^® Protein Short Peptides Beverage is an effective treatment for hypoalbuminemia in liver cirrhosis, without an increased risk of complications.

Keywords: Hypoalbuminemia; Shu Fu Pai® Protein Short Peptides Beverage; clinical efficacy; human albumin; liver cirrhosis.